Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy.

NCT06687876 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT06687876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06687876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy.
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 2
Overall status
Recruiting
Start date
March 9, 2025
Completion date
December 31, 2030
Enrollment
14 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

oesophageal adenocarcinoma, tumor microenvironment